Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16228294 | 1.00 | KCNH2 (0.78) | KCNH2SMN1; SMN2CCR1CCR8CYP19A1 | |
| SCHEMBL9971347 | 1.00 | KCNH2 (0.78) | KCNH2SMN1; SMN2CCR1CCR8CYP19A1 | |
| SCHEMBL22299298 | 1.00 | KCNH2 (0.78) | KCNH2SMN1; SMN2CCR1CCR8CYP19A1 | |
| SCHEMBL16228298 | 1.00 | KCNH2 (0.78) | KCNH2SMN1; SMN2CCR1CCR8CYP19A1 | |
| SCHEMBL26162438 | 1.00 | KCNH2 (0.78) | KCNH2SMN1; SMN2CCR1CCR8CYP19A1 | |
| SCHEMBL10373980 | 0.98 | KCNH2 (0.74) | KCNH2SMN1; SMN2CCR1CCR8 | |
| SCHEMBL681574 | 0.92 | KCNH2 (0.64) | KCNH2SMN1; SMN2CCR1CCR8 | |
| SCHEMBL24973117 | 0.88 | KCNH2 (1.00) | KCNH2CYP19A1GPR84 | |
| SCHEMBL10790586 | 0.88 | KCNH2 (1.00) | KCNH2CYP19A1GPR84 | |
| SCHEMBL6463178 | 0.88 | KCNH2 (1.00) | KCNH2CYP19A1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592226-B2 | Solenopsin and derivatives, therapeutic compositions; and methods related thereto | EMORY UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150306082-A1 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| US-20140335079-A1 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306082-A1 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO | AGPS, CYP27A1, CYP11A1 | KCNH2 4485/4885SMN1; SMN2 1838/4885CCR1 3872/4885 |
| US-20140335079-A1 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO | AGPS, CYP27A1, CYP11A1 | KCNH2 4485/4885SMN1; SMN2 1838/4885CCR1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.